Skip to main content
Figure 3 | Cancer Cell International

Figure 3

From: Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC)

Figure 3

MALDI-TOF-MS results of native and pegylated rhArg11. (A) MW of the native rhArg11 is ~35.5 kDa. (B) Numbers 1–6 under the peaks correspond to the number of PEG conjugated; the numbers on the peaks indicate the mass-to-charge (m/z) ratio values.

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us